Comparative evaluation explores dementia prevention with SGLT2 inhibitors versus dulaglutide in type 2 diabetes, suggesting neuroprotective effects remain uncertain.
Both sodium–glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1 RAs) may have neuroprotective effects in patients with type 2 diabetes (T2D). However, their comparative effectiveness in preventing dementia remains uncertain.
No takes yet. Share an insight, caveat, or question.
Hong et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: